Date: 2012-06-15
Type of information: Licensing agreement
Compound: OTX015
Company: Oncoethix (Switzerland) Mitsubishi Tanabe Pharma (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: OTX015 is a synthetic small molecule targeted to BET bromodomains 2/3/4 (BRD2/3/4). Recent scientific publications have shown that inhibition of BRD2/3/4 down-regulates MYC transcription, followed by genome-wide down regulation of MYC-dependent target genes. Previously, pharmacological inhibition of MYC—a transcription factor that is a master regulator of diverse cellular functions with a major role in a variety of human neoplasias—was not considered possible.
Disease:
Details: * On June 15 2012, OncoEthix, a Swiss-based company specializing in oncology drug development, has announced that it has in-licensed a compound, OTX015, from Mitsubishi Tanabe Pharma Corporation ( MTPC). MTPC had successfully completed Phase 1 clinical studies in healthy volunteers and licensed the compound to OncoEthix to take advantage of its expertise in the development of novel oncology drugs. OncoEthix plans to initiate clinical trials later this year.
Financial terms:
Latest news:
